摘要
目的探讨甲氨蝶呤联合艾拉莫德治疗类风湿关节炎(RA)的临床疗效。方法 110例RA患者随机分为观察组40例、A对照组38例和B对照组32例,观察组使用甲氨蝶呤联合艾拉莫德治疗,A对照组使用甲氨蝶呤单独治疗,B对照组使用艾拉莫德单独治疗。连续治疗12个月。结果治疗后,各组临床症状均较治疗前均显著减轻(P<0.05或P<0.01),视觉模拟评分(VAS评分)均显著降低(P<0.01),红细胞沉降率(ESR)、血清C反应蛋白(CRP)及类风湿因子(RF)均显著降低(P<0.01);组间比较,观察组治疗后晨僵时间、关节压痛数、VAS评分均较A、B对照组显著降低(P<0.01),而关节肿胀数仅较A对照组显著降低(P<0.01)。结论甲氨蝶呤联合艾拉莫德治疗RA较单用疗效更好,且不增加不良反应。
Objective To explore the clinical effect of methotrexate （MTX） combined with iguratimod on treatment of rheumatoid arthritis （RA）. Methods A total of 110 RA patients were randomly divided into three groups. Observation group （n = 40） was treated with MTX and igura- timod, control group A （ n = 38 ） was treated with single MTX and control group B （ n = 32） was treated with single iguratimod. Results After treatment, the clinical symptoms significantly im- proved in all the groups （P〈0.05 or P〈0.01）, visual analogue scale （VAS）, erythrocyte sedi- mentation rate （ESR）, and serum C-reactive protein （CRP） and rheumatoid factor （RF） decreased significantly （P 〈 0.01）. Morning stiffness duration, tender joint count and VAS score in the ob- servation group were significantly lower than those in the control group A and control group g （P 〈 0.01 ）, but swollen joint count in the observation group was significantly lower than control that in the control group A （P 〈 0.01 ）. Conclusion MTX combined with iguratimod show a better clini- cal efficacy in treating RA patients.
出处
《实用临床医药杂志》
CAS
2015年第1期120-122,共3页
Journal of Clinical Medicine in Practice
基金
中国高校医学期刊临床专项资金(11321416)
关键词
类风湿关节炎
甲氨蝶呤
艾拉莫德
红细胞沉降率
C反应蛋白
类风湿因子
rheumatoid arthritis
methotrexate
iguratimod
erythrocyte sedimentation rate
C-reactive protein
rheumatoid factor
